http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-076836-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D407-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| filingDate | 2010-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-076836-A1 |
| titleOfInvention | INHIBITORS OF THE EXTERNAL RENAL MEDULAR POTASSIUM CHANNEL |
| abstract | The compounds of formula 1 are useful as diuretics and natriuretics and are therefore useful for the therapy and prophylaxis of disorders resulting from excessive retention of salts and water, including cardiovascular diseases such as hypertension and chronic and acute heart failure. Claim 1: A compound having the structural formula (1) and pharmaceutically acceptable salts thereof, wherein formula (2) represents a heterocyclic ring selected from the group consisting of the group of formulas (3); Z1 is selected from the group consisting of formulas (4); Z2 is selected from the group consisting of formulas (5); X is selected from the group consisting of -H, -OH, -C1-3alkyl, -F, oxo, NH2 and -CH3; Y is selected from the group consisting of -H, -OH, -C1-3alkyl, -F, oxo, NH2 and -CH3; each of X1 and Y1 is independently selected from the group consisting of -H and -CH3; each of X2 and Y2 is -O-; with the proviso that when X is oxo then X1 is absent and when Y is oxo then Y1 is absent; and with the additional condition that when neither X2 nor Y2 are present, then at least one of X and Y is selected from the group consisting of -OH, -C1-3alkyl, -F and oxo; each of R1 and R2 is independently selected from the group consisting of -H, -halo, -C3-6 cycloalkyl, -OR8, -SR8, -SOR8, -SO2R8, - (CH2) nOR8 and C1-6 alkyl optionally substituted with 1-3 of -F; one of R3a and R3b is selected from the group consisting of -CN and -NO2 and the other is Re; one of R4a and R4b is selected from the group consisting of -CN and -NO2 and the other is Rf; each of R5 and R6 is independently selected from the group consisting of -H, -C1-6 alkyl, -C3-6 cycloalkyl, -CF3, -CHF2, -CH2F and -CH2OH; R7 is selected from the group consisting of -H, -CH3, -CF3, -CH2F, -CHF2 and -CH2OH; each of Ra and Rb is independently selected from the group consisting of (a) -H, (b) halo, (c) -C 1-6 alkyl optionally substituted with 1-3 of -F, (d) -C3 cycloalkyl -6, (e) -C1-3alkyl optionally substituted with 1-3 of -F, (f) -OR8, (g) -CO2C1-6alkyl optionally substituted with 1-3 of -F, (h) - ( CH2) nOR8, (i) -SR8, (j) -SOR8, (k) -SO2R8, (l) -NHCOR8 and (m) -NHSO2R8; each of Rc and Rd is independently selected from the group consisting of (a) -H, (b) halo, (c) -C 1-6 alkyl optionally substituted with 1-3 of -F, (d) -C3 cycloalkyl -6, (e) -C1-3alkyl optionally substituted with 1-3 of -F, (f) -OR8, (g) -CO2C1-6alkyl optionally substituted with 1-3 of -F, (h) - ( CH2) OR8, (i) -SR8, (j) -SOR8, (k) -SO2R8, (l) -NHCOR8 and (m) -NHSO2R8; each of Re and Rf is independently selected from the group consisting of (a) -H, (b) halo, (c) -C 1-6 alkyl optionally substituted with 1-3 of -F, (d) -C3 cycloalkyl -6, (e) -C1-3alkyl optionally substituted with 1-3 of -F, (f) -OR8, (g) - CO2C1-6 alkyl optionally substituted with 1-3 of -F, (h) - ( CH2) nOR8, (i) -SR, (j) -SOR8, (k) -SO2R8, (l) -NHCOR8 and (m) -NHSO2R8; n is an integer selected from 1, 2 and 3; and R8 is independently selected in each case from the group consisting of -H, -C3-6cycloalkyl and -C1-6 alkyl optionally substituted with 1-3 of -F. |
| priorityDate | 2009-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962 |
Total number of triples: 36.